Evidence map›Paper›PMID 31542851›Full record

ArticleInternational journal of hematology2019

Evaluation of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in Japanese healthy donors: a prospective study.

Keijiro Sato, Ken Ishiyama, Go Aoki, Hiroyuki Maruyama, Noriaki Tsuji, Mikoto Tanabe, Yoshitaka Zaimoku, Hidehiro Sato, Hirohito Yamazaki, Masaki Yamaguchi and 2 more

Abstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Keijiro SatoDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Ken IshiyamaDepartment of Hematology, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan. ishiyama-knz@umin.ac.jp.ORCID http://orcid.org/0000-0002-6189-0620
Go AokiDepartment of Hematology, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
Hiroyuki MaruyamaDepartment of Hematology, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
Noriaki TsujiDepartment of Hematology, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
Mikoto TanabeDepartment of Hematology, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
Yoshitaka ZaimokuDepartment of Hematology, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
Hidehiro SatoDepartment of Transfusion Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Hirohito YamazakiDepartment of Transfusion Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Masaki YamaguchiDepartment of Hematology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
Akiyoshi TakamiDepartment of Hematology, Aichi Medical University, Nagakute, Japan.
Shinji NakaoDepartment of Hematology, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
Kanazawa University Hospital · JPAichi Medical University · JPIshikawa Prefectural Central Hospital · JPToyama Prefectural Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A "biosimilar" is a biotechnological product with a lower cost profile and equivalent efficacy and safety to the originator, but post-marketing clinical evaluation of biosimilar products has not been adequately conducted. We prospectively investigated the utility of biosimilar filgrastim in 13 peripheral blood stem cell (PBSC) donors from June 2014 to January 2017. In addition, we retrospectively compared these to another 13 PBSC donors mobilized with the originator filgrastim in the same period. Donor characteristics were equivalent between the groups. The median number of CD34

Indexed as

Tissue DonorsAdultAntigens, CD34Biosimilar PharmaceuticalsFemaleFilgrastimGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHumansJapanMaleMiddle AgedPeripheral Blood Stem CellsProspective StudiesRetrospective StudiesAntigens, CD34Biosimilar PharmaceuticalsFilgrastimGranulocyte Colony-Stimulating FactorBiosimilarGranulocyte colony-stimulating factorHematopoietic stem cell mobilization

Identifiers

PMID31542851
OpenAlexW2974713978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.